The AIM2 inflammasome: A novel biomarker and target in cardiovascular disease

Pharmacol Res. 2022 Dec:186:106533. doi: 10.1016/j.phrs.2022.106533. Epub 2022 Nov 2.

Abstract

Absent in melanoma 2 (AIM2) is a cytoplasmic sensor that recognises the double-strand DNA. AIM2 inflammasome is a protein platform in the cell that initiates innate immune responses by cleaving pro-caspase-1 and converting IL-1β and IL-18 to their mature forms. Additionally, AIM2 inflammasome promotes pyroptosis by converting Gasdermin-D (GSDMD) to GSDMD-N fragments. An increasing number of studies have indicated the important and decisive roles of the AIM2 inflammasome, IL-1β, and pyroptosis in cardiovascular diseases, such as coronary atherosclerosis, myocardial infarction, ischaemia/reperfusion injury, heart failure, aortic aneurysm and ischaemic stroke. Here, we review the molecular mechanism of the activation and effect of the AIM2 inflammasome in cardiovascular disease, revealing new insights into pathogenic factors that may be targeted to treat cardiovascular disease and related dysfunctions.

Keywords: AIM2 inflammasome; Coronary atherosclerosis; Heart failure; Ischaemic stroke; Myocardial infarction; Therapeutic target.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers
  • Brain Ischemia*
  • Cardiovascular Diseases* / drug therapy
  • DNA-Binding Proteins / metabolism
  • Humans
  • Inflammasomes / metabolism
  • Interleukin-1beta / metabolism
  • Melanoma*
  • Stroke*

Substances

  • Inflammasomes
  • DNA-Binding Proteins
  • Interleukin-1beta
  • Biomarkers
  • AIM2 protein, human